Shen L, et al. – In this study, the physicians aimed to identify the clinical significance of serum autoantibodies against dickkopf–1 (DKK1) and assess their feasibility in the immunodiagnosis and prognosis of non–small cell lung cancer (NSCLC). They suggested that identified linear epitopes of antigens by peptide microarray were easily available and subtype classification of DKK1 autoantibodies as novel biomarkers for the diagnosis and prognosis of NSCLC. This research highlighted the antibody subtype to peptides 37–54 (Pep B) as the most valuable biomarker for favorable prognosis of NSCLC.